Gilead Not Bullet-Proof After All: Harvoni US Sales Tumble More Than 50%
This article was originally published in The Pink Sheet Daily
Company says revenue per patient has decreased due to increasing number of public-payer treatment starts and discounts required to start less-sick patients on therapy.
You may also be interested in...
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.